학술논문

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
Document Type
Article
Source
In European Journal of Cancer April 2024 201
Subject
GO
Language
ISSN
0959-8049